The FDA Approves Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Stage II And III Early Breast Cancer At High Risk Of Recurrence
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Novartis' drug Kisqali (Ribociclib) for use in combination with an aromatase inhibitor for treating certain types of early breast cancer. This approval is significant for patients with hormone receptor-positive/HER2-negative stage II and III early breast cancer at high risk of recurrence.
September 18, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis received FDA approval for Kisqali, a drug for early breast cancer treatment, which could boost its market position and revenue in oncology.
The FDA approval of Kisqali for a new indication expands Novartis' oncology portfolio, likely leading to increased sales and strengthening its market position in cancer treatment. This positive regulatory news is expected to have a favorable impact on Novartis' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90